Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Hizentra for CIDP Treatment

CSL Behring news release; 2018 Mar 16

CSL Behring recently announced that the US Food and Drug Administration (FDA) has approved Hizentra (immune globulin subcutaneous [human] 20% liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. CSL Behring is headquartered in Melbourne, Australia, and King of Prussia, PA, in the US.

Indications: Hizentra is indicated for the treatment of:

  • Primary immunodeficiency (PI) in adults and pediatric patients aged ≥2 years.
  • Maintenance therapy in adults with CIDP.

Dosage/administration: Hizentra is for subcutaneous infusion only. Before switching to Hizentra, physicians should obtain the patient’s serum IgG trough level to guide subsequent dose adjustments. Additional information about dosing can be found here:

Adverse reactions: The most common adverse reactions observed in ≥5% of study subjects were local infusion site reactions, headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain (upper), migraine, arthralgia, pain, fall and nasopharyngitis.


FDA approves Hizentra (immune globulin subcutaneous [human] 20% liquid) for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). [news release]. Melbourne, Australia, and King of Prussia, PA: CSL Behring. March 16, 2018. Accessed March 27, 2018.

This Week's Must Reads

Proximity to Major Roadway, Stroke Risk Linked, Stroke; ePub 2018 Mar 14; Kulick, et al

Poor Sleep Quality and QOL in Patients with COPD, Sleep; ePub 2018 Mar 9; Zeidler, Martin, et al

ED Transfers for IS/TIA More than Doubled, 2006-14, Neurology; ePub 2018 Apr 4; George, Doyle, et al

Arterial Stiffness Major Risk Factor for Dementia, Neurology; ePub 2018 Mar 16; Hughes, et al

Reduced Contrast Sensitivity and Cognitive Decline, Ann Neurol; ePub 2018 Mar 8; Ward, Gelfand, et al

Must Reads in FDA Actions

FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16

FDA Approves Apadaz for Acute Pain Relief, KemPharm, Inc. news release; 2018 Feb 23

FDA Permits Marketing of Stroke Alert Software, FDA news release; 2018 Feb 13